Literature DB >> 7678578

The alcohol-altered liver membrane antibody and hepatitis C virus infection in the progression of alcoholic liver disease.

S Takase1, M Tsutsumi, H Kawahara, N Takada, A Takada.   

Abstract

Progression of alcoholic liver disease is closely related to drinking habits. However, prognosis of alcoholic liver disease is not determined just by drinking habits, but also by other factors. In this study, the roles of alcohol-altered liver membrane antibody and hepatitis C virus infection were analyzed in alcoholic patients who were followed up for various lengths of time. Serial changes of liver histological appearance were analyzed in 39 patients with alcoholic liver disease who were followed for long periods (49.7 +/- 34.3 mo) and who underwent liver biopsy at least two times. Prognoses of 35 patients with alcoholic cirrhosis who were followed for more than 1 yr were also evaluated. Development of cirrhosis in alcoholic liver disease was significantly higher in the alcohol-altered liver membrane antibody-positive patients than in the patients negative for this antibody. On the other hand, hepatitis C virus markers were not related to development of cirrhosis. However, hepatocellular carcinoma developed more frequently in the hepatitis C virus marker-positive patients. In patients with cirrhosis, the cumulative rates of hepatocellular carcinoma development were significantly higher in the hepatitis C virus marker-positive patients than in the marker-negative patients. Cumulative survival rates in the hepatitis C virus marker-positive patients were significantly lower than rates in the hepatitis C virus marker-negative patients, even in noncancer patients. However, such differences were not observed in the alcohol-altered liver membrane antibody-positive and alcohol-altered liver membrane antibody-negative cirrhotic patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678578

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

1.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

2.  The management of chronic hepatitis C virus infection.

Authors:  J C Booth; J L Brown; H C Thomas
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

Review 3.  The pathogenesis of alcoholic liver disease.

Authors:  R Goldin
Journal:  Int J Exp Pathol       Date:  1994-04       Impact factor: 1.925

Review 4.  Pathophysiology and treatment of hepatitis C.

Authors:  H C Thomas; J Booth; J Brown
Journal:  Drugs       Date:  1996       Impact factor: 9.546

5.  Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis.

Authors:  T Chiba; Y Matsuzaki; M Abei; J Shoda; T Aikawa; N Tanaka; T Osuga
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

6.  Immune mechanisms in alcoholic liver disease.

Authors:  Emanuele Albano; Matteo Vidali
Journal:  Genes Nutr       Date:  2009-10-07       Impact factor: 5.523

Review 7.  Inflammatory status in human hepatic cirrhosis.

Authors:  María Martínez-Esparza; María Tristán-Manzano; Antonio J Ruiz-Alcaraz; Pilar García-Peñarrubia
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

8.  Survival rates of early-stage HCV-related liver cirrhosis patients without hepatocellular carcinoma are decreased by alcohol.

Authors:  Masayoshi Yamada; Hisakazu Shiroeda; Ranji Hayashi; Hirokazu Yano; Katsuaki Sato; Mikihiro Tsutsumi; Tomiyasu Arisawa
Journal:  J Clin Biochem Nutr       Date:  2010-04-10       Impact factor: 3.114

9.  Role of adaptive immunity in alcoholic liver disease.

Authors:  Emanuele Albano
Journal:  Int J Hepatol       Date:  2011-09-07

Review 10.  Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care.

Authors:  Zobair M Younossi; Haesuk Park; Douglas Dieterich; Sammy Saab; Aijaz Ahmed; Stuart C Gordon
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.